Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.
暂无分享,去创建一个
Michael J. Keiser | P. Sullivan | J. Dudley | S. Purcell | P. Sklar | C. Hultman | D. Ruderfer | J. Moran | S. Scott | B. Kidd | P. Kenny | A. Kähler | A. Charney | B. Readhead | S. Scott
[1] C. Spencer,et al. Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.
[2] Jennifer G. Robinson,et al. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. , 2014, Human molecular genetics.
[3] H. Tornqvist,et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial , 2014, Diabetes, obesity & metabolism.
[4] C. Altar,et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review , 2014, International clinical psychopharmacology.
[5] M. Leboyer,et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate , 2014, European Archives of Psychiatry and Clinical Neuroscience.
[6] Eric S. Lander,et al. A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.
[7] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[8] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[9] S. Leucht,et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis (vol 382, pg 951, 2013) , 2013 .
[10] Dimitris Mavridis,et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.
[11] Simon C. Potter,et al. Genome-wide Association Analysis Identifies 14 New Risk Loci for Schizophrenia , 2013, Nature Genetics.
[12] M. De Hert,et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review , 2013, Therapeutic advances in psychopharmacology.
[13] P. DeRosse,et al. Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia , 2013, Schizophrenia Research.
[14] Robert V Farese,et al. DGAT1 mutation is linked to a congenital diarrheal disorder. , 2012, The Journal of clinical investigation.
[15] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[16] Colm O'Dushlaine,et al. INRICH: interval-based enrichment analysis for genome-wide association studies , 2012, Bioinform..
[17] G. Remington,et al. Treatment resistant schizophrenia and response to antipsychotics: A review , 2011, Schizophrenia Research.
[18] J. Kleinman,et al. Spatiotemporal transcriptome of the human brain , 2011, Nature.
[19] A. Malhotra,et al. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction , 2011, Expert opinion on drug metabolism & toxicology.
[20] Tanya M. Teslovich,et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.
[21] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[22] J. McGrath,et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. , 2008, Epidemiologic reviews.
[23] Dolores Corella,et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.
[24] Anders Sundström,et al. The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.
[25] R. Yolken,et al. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. , 2007, Schizophrenia bulletin.
[26] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[27] Patrick F Sullivan,et al. Recurrence risks for schizophrenia in a Swedish National Cohort , 2006, Psychological Medicine.
[28] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[29] B. Hawes,et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Russell,et al. Clinical importance of the cytochromes P450 , 2002, The Lancet.
[31] J. Darnell,et al. Fragile X Mental Retardation Protein Targets G Quartet mRNAs Important for Neuronal Function , 2001, Cell.
[32] E. Hewlett,et al. Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. , 1982, Science.
[33] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .